Data / Form D filings / Euclises Pharmaceuticals, Inc.
Euclises Pharmaceuticals, Inc.: Form D filings
Euclises Pharmaceuticals, Inc., a pharmaceuticals company in St. Louis, MO, filed 5 Form D notices with the SEC between 2012 and 2016. The latest, on December 1, 2016, reports $1.2 million sold of a $2.7 million offering to 5 investors.
Find out what Euclises Pharmaceuticals, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 4320 FOREST PARK AVENUE, SUITE 303, St. Louis, MO, 63108
- Phone
- (314) 604-2850
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2011
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(c)
- SEC identifier (CIK)
- 1550350
The full lists. Form D filings in Missouri: 379 rows, $18.95, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Dec 1, 2016 | Amendment | $2,711,198 | $1,216,913 | $1,494,285 | 5 | Nov 9, 2015 | sec.gov |
| Oct 1, 2015 | New notice | $662,603 | $0 | $662,603 | 0 | Yet to occur | sec.gov |
| Oct 1, 2015 | Amendment | $1,851,250 | $1,851,250 | $0 | 9 | Dec 30, 2013 | sec.gov |
| Jan 13, 2014 | New notice | $1,400,000 | $300,000 | $1,100,000 | 1 | Dec 30, 2013 | sec.gov |
| May 17, 2012 | New notice | $400,000 | $174,998 | $225,002 | 1 | May 4, 2012 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Charles A. Bolten | Director | |
| John J. Talley | Director | |
| Robert J. Calcaterra | Director | |
| Rajesh J. Devraj | Director | |
| Rick J. Ryan | Director | |
| Robert A. Beardsley | Director | |
| Bobby W. Sandage, Jr. | Executive Officer, Director |
Other pharmaceuticals companies in Missouri that filed recently
- Immunophotonics, Inc. $10.1 million · Sep 4, 2026
Every Form D from the week of Nov 28, 2016 · All recent filings in Missouri · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Euclises Pharmaceuticals, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.